MARIBETH RIDAY: Open Payments
NPI 1720241474 · WATSONVILLE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,223 in 18 payments from 8 companies in 2025. Trend: 2023 $774 · 2024 $1,116 · 2025 $1,223
Food & beverage: $1,223
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $296 |
| Teva Pharmaceuticals USA, Inc. | 2 | $250 |
| Janssen Pharmaceuticals, Inc | 2 | $249 |
| Neurocrine BioSciences, Inc. | 1 | $127 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $110 |
| Alkermes, Inc. | 1 | $35 |
| Indivior Inc. | 1 | $32 |
Products named: CAPLYTA, INVEGA SUSTENNA, INGREZZA, Auvelity, UZEDY, AUSTEDO XR, ABILIFY MAINTENA, LYBALVI.
Industry payments across CA — which companies pay providers there.
